Loading
CYTO-PV settled the most basic question in PV: keeping the haematocrit under 45 percent gives far fewer serious clots and cardiovascular deaths than a looser target.
CYTO-PV randomised 365 adults with polycythaemia vera to a haematocrit target below 45 percent or between 45 and 50 percent, achieved with phlebotomy and hydroxyurea. After a median of 31 months the primary endpoint of cardiovascular death or major thrombosis occurred in 2.7 percent of the low-target group and 9.8 percent of the high-target group (Marchioli and colleagues, New England Journal of Medicine 2013). The result made 45 percent the universal target.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
365 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Cardiovascular death or major thrombosisprimary | Haematocrit below 45% | 182 | 2.7% | - | - | - |
| Haematocrit 45 to 50% | 183 | 9.8% |
Shares Phlebotomy (venesection), Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
Shares Hydroxyurea (hydroxycarbamide), Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.